<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209297">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363194</url>
  </required_header>
  <id_info>
    <org_study_id>VEG10005</org_study_id>
    <nct_id>NCT00363194</nct_id>
  </id_info>
  <brief_title>A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients</brief_title>
  <official_title>An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Single Doses of Pazopanib in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is two-part study (Part I/Part II). Part I is designed to determine the effect of a low
      and high fat meal on the pharmacokinetics of single dose pazopanib (GW572016). Part II is
      designed to allow patients continued access to study drug in a multiple dosing regimen.
      Patients who are receiving clinical benefit on that regimen will go into the long term
      rollover study VEG105430 provided they are stable for 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I optimal food / fast recommendation</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Activity</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (GW786034)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Confirmed advanced solid tumor(s)

          -  Must have adequate blood, liver, and kidney function.

          -  Must be willing to abstain from intercourse from 2 weeks prior to administration of
             the first dose of study medication until 28 days after the final dose of study
             medication or be willing to consistently and correctly use an acceptable method of
             birth control.

        Exclusion criteria:

          -  Patients with certain heart problems or history of bleeding within a month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 17, 2010</lastchanged_date>
  <firstreceived_date>August 11, 2006</firstreceived_date>
  <firstreceived_results_disposition_date>March 17, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Pazopanib GW786034 Advanced cancer Metastatic cancer</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
